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The uptake and processing of dietary lipids by the small intestine is a multistep process that involves several
steps including vesicular and protein transport. The GTPase ADP-ribosylation factor-related protein 1
(ARFRP1) controls the ARF-like 1 (ARL1)-mediated Golgi recruitment of GRIP domain proteins which in
turn bind several Rab-GTPases. Here, we describe the essential role of ARFRP1 and its interaction with
Rab2 in the assembly and lipidation of chylomicrons in the intestinal epithelium. Mice lacking Arfrp1 specif-
ically in the intestine (Arfrp1
vil2/2) exhibit an early post-natal growth retardation with reduced plasma triacyl-
glycerol and free fatty acid concentrations. Arfrp1
vil2/2 enterocytes as well as Arfrp1 mRNA depleted Caco-2
cells absorbed fatty acids normally but secreted chylomicrons with a markedly reduced triacylglycerol con-
tent. In addition, the release of apolipoprotein A-I (ApoA-I) was dramatically decreased, and ApoA-I accumu-
lated in the Arfrp1
vil2/2 epithelium, where it predominantly co-localized with Rab2. The release of
chylomicrons from Caco-2 was markedly reduced after the suppression of Rab2, ARL1 and Golgin-245.
Thus, the GTPase ARFRP1 and its downstream proteins are required for the lipidation of chylomicrons
and the assembly of ApoA-I to these particles in the Golgi of intestinal epithelial cells.
INTRODUCTION
The adequate absorption of lipids is essential for all mamma-
lian species because of their inability to synthesize essential
fatty acids and fat-soluble vitamins. The lipid absorption
requires several events such as hydrolysis, uptake into the
enterocytes, re-esteriﬁcation and transport into the lymph or
portal blood (1–3). About 95% of the lipids in the diet are
composed of triacylglycerols which are cleaved via lipolysis
to produce free fatty acids and 2-monoacylglycerol. Absorbed
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Advance Access published on April 14, 2012fatty acids and monoacylglycerols are bound to intracellular
proteins (fatty acid transport proteins, FATP’s) and/or
rapidly converted to triacylglycerols to prevent cellular mem-
brane disruption. The triacylglycerol produced at the level of
the endoplasmic reticulum (ER) is either incorporated into
pre-chylomicrons within the ER lumen or shunted to triacyl-
glycerol storage pools. The pre-chylomicrons exit the ER in
a specialized transport vesicle, the PCTV (pre-chylomicron
transport vesicle), which is the rate-limiting step in the intra-
cellular transit of triacylglycerol across the enterocyte. The
pre-chylomicrons are further processed in the Golgi and trans-
ported to the basolateral membrane via a separate vesicular
system for exocytosis into the intestinal lamina propria (2,3).
Little is known about post-ER maturation and secretion
process of chylomicrons in the Golgi.
Here, we describe the essential role of a small
trans-Golgi-associated GTPase for the maturation and lipida-
tion of chylomicrons. ARFRP1 (ADP-ribosylation factor-
related protein 1) is a member of the family of ARFs of
GTPases which play a pivotal role in the regulation of mem-
brane trafﬁc (4–6). Activated, GTP-bound ARFRP1 associ-
ates with trans-Golgi membranes (7,8) and is required for
the recruitment of ARF-like 1 (ARL1) and its effector
Golgin-245 to the trans-Golgi (7,9,10). ARFRP1 is essential
for the normal growth of lipid droplets by mediating the trans-
fer of newly formed small lipid particles to the large storage
droplets because mice lacking Arfrp1 speciﬁcally in adipo-
cytes (Arfrp1
ad2/2) were lipodystrophic and exhibited a de-
fective lipid droplet formation in adipose tissues (11).
In order to deﬁne the role of ARFRP1 in intestinal nutrient
absorption, we characterized intestine-speciﬁc Arfrp1 null
mutants (Arfrp1
vil2/2 mice) with regard to the lipid metabol-
ism. As a consequence of the defective lipidation and matur-
ation of chylomicrons in the Golgi, the triacylglycerol
concentration in the plasma of Arfrp1
vil2/2 mice was marked-
ly reduced resulting in growth retardation.
RESULTS
Growth retardation and lethality of Arfrp1
vil2/2 mice
Mice lacking intestinal Arfrp1 (Arfrp1
vil2/2) were born with
no apparent differences in size. Subsequently, poor growth
(Fig. 1A) and lethality (Fig. 2A) became evident at the age
of 3 days. Measurement of body composition indicated that
both fat mass and lean mass of Arfrp1
vil2/2 mice were
reduced (Fig. 1B) resulting in no alteration of the relative
body composition. In addition, the weights of the liver and
kidney and the length of the small intestine were signiﬁcantly
reduced in Arfrp1
vil2/2 mice (Supplementary Material,
Table S3). However, normalized for the reduced body
weight and length of Arfrp1
vil2/2 mice, the relative intestinal
length did not differ (Arfrp1
ﬂox/ﬂox: 3.74+0.19 vs.
Arfrp1
vil2/2: 3.60+0.20). In parallel with the marked
growth retardation, we detected signiﬁcantly lower levels of
glucose, triacylglycerol, free fatty acids and cholesterol in
the plasma of Arfrp1
vil2/2 mice (Supplementary Material,
Table S4), whereas plasma concentrations of insulin were
not altered (Arfrp1
ﬂox/ﬂox: 0.299+0.047 vs. Arfrp1
vil2/2:
0.279+0.029 mg/l). In order to test whether these blood
parameters differ due to altered liver function, we studied
the expression of mRNA of enzymes involved in glucose
and lipid metabolism. Since we did not detect differences,
for example, in the mRNA level of the gluconeogenic
enzyme PEPCK (Pck1) and lipid metabolism (Acaca, Fasn,
Scd1, Cpt1a, Hadhsc; Supplementary Material, Fig. S1), we
conclude that Arfrp1
vil2/2 mice suffer from the lack of nutri-
ents potentially due to malabsorption.
We tried to reduce the lethality of Arfrp1
vil2/2 mice by a
dietary intervention and tested their survival rate under differ-
ent diets, a standard chow diet (10% fat, 70% carbohydrates
and 20% protein; percent of calories), a fat-depleted diet
(0.2% fat, 73.2% carbohydrates and 26.5% protein) and a
carbohydrate-free fat-enriched diet (72% fat and 28%
protein). Under fat-depleted and standard diet conditions, the
survival of Arfrp1
vil2/2 mice (41 and 51% after 35 days, re-
spectively) was much better than under the fat-enriched diet
(14%, Fig. 2A). These data suggested that Arfrp1 is required
for an adequate absorption of fat in the small intestine.
Reduced fat absorption of Arfrp1
vil2/2 mice
Oral fat tolerance tests performed with 5-week-old mice indi-
cated an impaired fat absorption in Arfrp1
vil2/2 mice: in con-
trast to controls (Arfrp1
ﬂox/ﬂox), Arfrp1
vil2/2 mice failed to
respond to a bolus of olive oil by an increase in plasma triacyl-
glycerol (Fig. 2B). Furthermore, the concentration of all fatty
acids, including essential and conditionally essential fatty
acids (linoleic acid, linolenic acid and g-linolenic acid),
were signiﬁcantly lower in the plasma of Arfrp1
vil2/2 than
in Arfrp1
ﬂox/ﬂox littermates (Supplementary Material,
Fig. S2A). Since defective intestinal fat absorption is asso-
ciated with deﬁciency in fat-soluble vitamins, we measured
vitamin E levels in the plasma and detected signiﬁcantly
lower levels in Arfrp1
vil2/2 than in control mice (Supplemen-
tary Material, Fig. S2B).
During oral glucose tolerance tests, blood glucose concen-
trations were essentially identical in both genotypes, indicat-
ing that glucose transport is not impaired in the absence of
Arfrp1 (Supplementary Material, Fig. S3A). Furthermore,
immunohistochemistry demonstrated that SGLT1 was exclu-
sively located at the apical membrane with no differences
between control and Arfrp1
vil2/2 mice (Supplementary Mater-
ial, Fig. S3B). Western blot analysis conﬁrmed that the expres-
sion of glucose transporters SGLT1 and GLUT2 is not
impaired in Arfrp1
vil2/2 mice (Supplementary Material,
Fig. S3C).
Levels of most essential and non-essential proteinogenic as
well as of non-proteinogenic amino acids were identical in the
plasma of Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice. Concentrations
of some amino acids like glycine, glutamine and glutamate
were higher in Arfrp1
vil2/2 than in control mice. Thus, the ab-
sorption of peptides and amino acids does not appear to be
impaired in the null mutants (Supplementary Material,
Fig. S3D).
Since the results described suggested that the growth retard-
ation of Arfrp1
vil2/2 mice is due to the speciﬁc impairment of
lipid absorption, we performed quantitative RT–PCR analysis
of several transcripts involved in fatty acid transport but failed
to detect differences in the expression of the fatty acid
Human Molecular Genetics, 2012, Vol. 21, No. 14 3129transporters FATP1, FATP4 and CD36 or the fatty acid
binding proteins FABP1 and FABP2. Transcripts of enzymes
involved in triacylglycerol synthesis (DGAT1 and DGAT2),
or those involved in chylomiron production such as ApoB,
ApoA-I and microsomal triacylglycerol transfer protein
(MTP), were not different between the genotypes (Supplemen-
tary Material, Fig. S4A). In addition, no differences in the sub-
cellular localization of FATP1, FABP1 and DGAT2 were
detected in the intestinal sections of Arfrp1
ﬂox/ﬂox and
Arfrp1
vil2/2 mice (Supplementary Material, Fig. S4B).
In order to test whether fatty acid uptake is affected in the
Arfrp1
vil2/2 epithelium, we stained lipids in sections of
jejunum of Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice with oil
red-O 2 h after mice received an oral gavage of olive oil.
We did not detect differences; both genotypes accumulated
lipid droplets in the intestinal epithelium (Supplementary Ma-
terial, Fig. S4C, left panels). This ﬁnding was conﬁrmed by
staining the lipid droplet coat protein TIP47 which also
showed a similar distribution in control and Arfrp1
vil2/2
cells (Supplementary Material, Fig. S4C, right panels).
These results indicate that neither the uptake of dietary fat
into the intestinal epithelium nor the lipid droplet formation
was affected in the absence of ARFRP1.
To test the impact of ARFRP1 on fat absorption in a system
of isolated cells, Arfrp1 expression was suppressed in the
colon carcinoma cell line Caco-2 by speciﬁc siRNA
(Fig. 2C, upper panel), cells incubated with
14C-labeled palmi-
tate for 24 h and the uptake, retention and basolateral release
of radioactivity were detected. The fatty acid uptake was not
signiﬁcantly different in Caco-2 cells transfected with
scrambled or Arfrp1-speciﬁc siRNA. However, the retention
of radioactivity was slightly but signiﬁcantly increased after
the down-regulation of Arfrp1, whereas the release on the
basolateral site was markedly reduced in siArfrp1 transfected
cells (Fig. 2C, lower panels), suggesting that the basolateral
export of lipids is affected after the disruption of Arfrp1.
Figure 1. Growth retardation of Arfrp1
vil2/2 mice. (A) Photographs of 3- and 28-day-old Arfrp1
ﬂox/ﬂox (+/+) and Arfrp1
vil2/2 (2/2) mice. Body weights of
Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice at the age of 3–28 days (n ¼ 10–12). (B) Fat mass (left panel) and lean mass (right panel) of Arfrp1
ﬂox/ﬂox (n ¼ 26) and
Arfrp1
vil2/2 mice (n ¼ 10) at the age of 28 days. Values are means of 10–26 mice+SEM (∗∗P , 0.01, ∗∗∗P , 0.001).
3130 Human Molecular Genetics, 2012, Vol. 21, No. 14Figure 2. Lethality and impaired triacylglycerol absorption of Arfrp1
vil2/2 mice. (A) Survival curves of Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice that were fed with
either a standard diet, fat-depleted or carbohydrate-free (carb-free) diet over a time period of 35 days. (B) Triacylglycerol concentrations during fat tolerance tests
performed in 5-week-old Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice. Values are means of eight mice+SEM (∗P , 0.05). (C) Impaired lipid release of Caco-2 cells
after the down-regulation of Arfrp1 expression. Caco-2 cells were transfected with scrambled or Arfrp1-speciﬁc siRNA and harvested 4 and 8 days after trans-
fection for western blot analysis with the anti-ARFRP1 antiserum (upper panel). Caco-2 cells were incubated with
14C-labeled palmitate for 24 h, and radio-
activity was determined in the basolateral medium reﬂecting the release (lower right panel) and in the lysates of the cells which indicates the retention
(lower middle panel). The uptake was calculated as the sum of radioactivity in the cell lysates and the basolateral medium (lower left panel). (D) Time
course of impaired lipid release from Arfrp1 knockdown Caco-2 cells. Cells were treated with
14C-labeled palmitate in the apical medium, and lipid transport
was measured at the indicated time points over the next 24 h. (E) Caco-2 cells transfected with scrambled or Arfrp1 siRNA were treated with 4 mM oleic acid for
24 h, and triacylglycerol levels in the cells (left panel) and the basal media (right panel) were measured. Values represent the mean+SEM from three inde-
pendent experiments (∗P , 0.05).
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was reduced early between 6 and 8 h after the addition of
radioactive palmitate to siArfrp-transfected cells (Fig. 2D).
Similar effects were observed when triacylglycerol levels
were measured in Caco-2 cells and in the basal medium
before and after incubation with oleic acid (Fig. 2E), suggest-
ing that re-esteriﬁed triacylglycerol within the epithelial cells
is not adequately released in the absence of Arfrp1.
Impaired chylomicron maturation in the Golgi of the
Arfrp1
vil2/2 intestinal epithelium
We next performed a fat tolerance test in the presence of
Triton WR-1339 which inhibits lipoprotein catabolism. Tria-
cylglycerol concentrations increased constantly over a time
period of 2 h in Arfrp1
ﬂox/ﬂox mice, whereas the triacylglycerol
concentrations of Arfrp1
vil2/2 mice were markedly lower
Figure 3. Reduced fat absorption of Arfrp1
vil2/2 mice. (A) A fat tolerance test was performed in 5 h fasted Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice, and plasma
triacylglycerol concentrations were detected at the indicated time points after the inhibition of lipoprotein catabolism by i.v. injection of Triton WR-1339.
(B) FPLC proﬁles of plasma samples of Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice (n ¼ 6) that received an oil bolus plus Triton WR-1339. Triacylglycerol concentra-
tions (mmol/l) were detected in the different fractions, chylomicron/VLDL (fractions 4–7), IDL (fractions 8,9), LDL (fractions 10–16) and HDL (fractions
17–24).
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vil2/2
mice (Fig. 3A). Strikingly, the plasma collected from
Arfrp1
vil2/2 mice 2 h after the oil bolus appeared to be trans-
parent and bright, while plasma from Arfrp1
ﬂox/ﬂox mice was
pale and turbid (data not shown). In contrast, Triton
WR-1339 injection without the oil bolus did not induce differ-
ences in the plasma triacylglycerol concentrations between
control and Arfrp1
vil2/2 mice (Supplementary Material,
Fig. S5), indicating that hepatic VLDL release is not affected
in Arfrp1
vil2/2 mice.
Fractionation of lipids into chylomicrons, IDL, LDL and
HDL by FPLC revealed a predominant reduction in triacylgly-
cerol concentrations in the chylomicron/VLDL fraction of
Arfrp1
vil2/2 mice (Fig. 3B).
Figure 4. Impaired assembly of ApoA-I to chylomicrons in the intestinal epithelium of Arfrp1
vil2/2 mice. (A) Plasma of 16 h fasted Arfrp1
ﬂox/ﬂox and
Arfrp1
vil2/2 mice (0 h) or of mice 4 h after receiving an oil bolus was analyzed by western blotting with the indicated antibodies. (B) Quantiﬁcation of the
levels of indicated Apo in the plasma of fasted and oil-treated Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice (n ¼ 10–11). (C) Triacylglycerol concentrations and
levels of the indicated Apo in the chylomicron fractions of plasma from Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice that had received an oil bolus plus Triton
WR-1339. (D) Immunohistochemical detection of indicated Apo in the intestinal section of Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice that were fasted and sacriﬁced
2 h after the olive oil bolus. Controls had free access to their regular standard diet. (E) Ultrastructural analysis of epithelial cells of Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2
mice. Pictures show representative Golgi structures of control and knockout epithelial cells. The arrows depict premature chylomicrons that were rarely visible in
the Golgi lumen of control cells but accumulated in that of Arfrp1
vil2/2 cells (G: Golgi apparatus; N: nucleus; CM: chylomicrons).
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they are packaged with apolipoproteins (Apo; B48, A-I and
A-IV) forming either chylomicrons or very-low-density lipo-
proteins (VLDLs) (3,12). We determined their levels in the
plasma of control and Arfrp1
vil2/2 mice after fasting and
4 h after an olive oil bolus (Fig. 4A and B). The ApoB100
level in the plasma of control mice signiﬁcantly increased
after the lipid application, whereas no changes were detectable
in the plasma of Arfrp1
vil2/2 mice. ApoB48 did not change in
response to the oil bolus; however, it was signiﬁcantly higher
in the null mutants. ApoA-IV increased when control mice
received the oil. Arfrp1
vil2/2 mice showed a similar trend
and the ApoA-IV level was constantly higher than in control
mice. ApoA-I exhibited the most striking difference with
markedly lower plasma concentrations in mice lacking intes-
tinal Arfrp1 (Fig. 4A and B).
We next studied the levels of Apo in the chylomicron, IDL/
LDL and HDL fractions obtained from the plasma of control
and Arfrp1
vil2/2 mice that received an oil bolus in combin-
ation with Triton WR-1339 after the 5-h fasting period. We
conﬁrmed the reduction in triacylglycerol levels in the chylo-
micron fraction (fractions 1–5) of Arfrp1
vil2/2 mice by
 85% (Fig. 4C) and obtained a similar reduction in choles-
terol concentration (Supplementary Material, Fig. S6). The
quantiﬁcation of the ApoB48 levels in the different fractions
indicated that they were also reduced in the chylomicron frac-
tion of Arfrp1
vil2/2 mice, but higher in denser fractions (IDL/
LDL), indicating that Arfrp1
vil2/2 mice secrete smaller chylo-
microns containing less triacylglycerol than control mice
(Fig. 4C). In addition, the ApoA-I levels in the chylomiron
fractions of Arfrp1
vil2/2 mice were much lower than in the
corresponding fractions of control plasma. Thus, enterocytes
Figure 4. Continued
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Human Molecular Genetics, 2012, Vol. 21, No. 14 3135release chylomicrons in the absence of Arfrp1, but the lipopro-
tein–triacylglycerol composition of chylomicrons differs
markedly between control and Arfrp1
vil2/2 mice.
Immunostaining of the Apo revealed ApoB generation in
both Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2 mice by the oil application.
However, it showed a dramatic accumulation of ApoA-IV and
ApoA-I in the intestinal epithelium of Arfrp1
vil2/2 mice
(Fig. 4D). This effect was conﬁrmed by western blotting
(Fig. 4D, lower panels) displaying a signiﬁcant increase in
ApoA-I in the intestinal epithelial cells. Ultrastructural analysis
of epithelial cells showed a different structure of the Golgi and
anaccumulationofprematurechylomicrons(arrows inFig.4E)
within the Golgi apparatus in the Arfrp1
vil2/2 epithelial cell. In
some knockout cells, we detected bloated vesicles in the area of
the Golgi which were enriched with small particles that appear
to be premature chylomicrons (lower right panels). Further-
more, we observed a lower number of mature chylomicrons
released from the Golgi apparatus of Arfrp1
vil2/2 cells than
detected in control cells (Fig. 4E).
We next suppressed Arfrp1 expression in Caco-2 cells and
determined the basolateral release of the Apo by western blot-
ting. As demonstrated in Figure 5A and B, the secretion of
ApoB100, ApoB48 and ApoA-IV increased when control
cells were treated with oleic acid. Interestingly, the concentra-
tion of ApoB100, ApoB48 and ApoA-IV in the basal medium
was higher when Arfrp1 expression was suppressed, whereas
that of ApoA-I—like in Arfrp1
vil2/2 mice—was signiﬁcantly
reduced (Fig. 5A and B). Since the effect on reduced ApoA-I
release after the suppression of Arfrp1 expression was smaller
than detected in Arfrp1
vil2/2 mice, we compared the Arfrp1
expression with the levels of ApoA-I in the basal medium.
As shown in Supplementary Material, Figure S7, both para-
meters show a strong correlation (R
2 ¼ 0.6639), indicating
that the effect of reduced ApoA-I secretion is higher when ex-
pression of Arfrp1 is lower. These data indicate a speciﬁc defect
in composing chylomicrons in Arfrp1 knockdown cells which
leads to reduced ApoA-I and higher levels of ApoB48 and
ApoA-IV and to a reduced capacity to carry triacylglycerol.
Since MTP transfers lipids to the lipoproteins, we tested
MTP expression and/or activity. The down-regulation of
Arfrp1 resulted in a rather moderate increase in MTP protein
levels and a slight increase in MTP activity, when cells were
treated in the absence of oleic acid, whereas no effects were
detectable in the presence of oleic acid (Supplementary Mater-
ial, Fig. S8A). We furthermore stained intestinal sections for
MTP but did not observe differences in its subcellular distribu-
tion (Supplementary Material, Fig. S8B).
In order to test whether the assembly of ApoA-I to the
chylomicron is required for their ﬁnal lipidation and matur-
ation, we suppressed ApoA-I expression in Caco-2 cells and
measured cellular triacylglycerol content and triacylglycerol
levels in the basal media before and after oleic acid treatment.
Here, we did not observe any differences (Fig. 5C), indicating
that the assembly of ApoA-I is not involved in the ﬁnal lipid
load to the chylomicrons.
Rab2 co-localizes with ApoA-I and accumulates at the
Golgi in the Arfrp1
vil2/2 intestinal epithelium
ARFRP1 is required for the recruitment of ARL1 and its ef-
fector, the GRIP domain protein Golgin-245, to trans-Golgi
Figure 5. Reduced release of ApoA-I after the inhibition of Arfrp1 expression
by siRNA in Caco-2 cells. (A) Scrambled and Arfrp1-siRNA transfected cells
were treated with or without oleic acid for 24 h and indicated proteins detected
in the basolateral medium or cell lysate by western blotting. (B) Quantiﬁcation
of levels of indicated Apo released into the basolateral medium of control
(scrambled) and Arfrp1 knockdown (siArfrp1) Caco-2 cells (n ¼ 8). (C)
Normal lipid release from Caco-2 cells after the down-regulation of ApoA-I
expression. Caco-2 cells were transfected with scrambled or ApoA1 siRNA
and differentiated as described in Materials and methods. Cells were treated
with 4 mM oleic acid for 24 h. The ApoA-I expression levels in the cell and
in the basal media were determined by western blotting (top panel). Triacyl-
glycerol levels were determined in the cells (bottom left panel) and the
basal media (bottom right panel). Values represent the mean+SEM.
3136 Human Molecular Genetics, 2012, Vol. 21, No. 14membranes (7,9,10). Recently, Sinka et al.( 13) discovered
that GRIP domain Golgins also bind four members of the
Rab family of small GTPases, Rab2, Rab6, Rab19 and
Rab30. Thus, we tested the hypothesis that the deletion of
Arfrp1 results in an altered distribution of Rab proteins and
that Rab proteins are co-localized with Apo.
Immunohistochemistry of Rab2 revealed a modiﬁed distri-
bution in Arfrp1
vil2/2 cells when compared with Arfrp1
ﬂox/ﬂox
cells of fed mice (Fig. 6A, left panels); an effect which
appeared more pronounced when mice had received an oil
bolus (Fig. 6B, left panels). In control enterocytes, Rab2 was
predominantly located in the cytosol and only partially
Figure 6. Co-localization of Rab2 with ApoA-I and its accumulation at Golgi membranes of intestinal Arfrp1
vil2/2 cells. (A and B) Immunohistochemical de-
tection of Rab2 (left panels), ApoA-I (middle panels) and the merged picture (right panels) in sections of the small intestine of 4-week-old Arfrp1
ﬂox/ﬂox and
Arfrp1
vil2/2 mice that had free access to their diet (A) or which received an oil bolus after a 16-h fasting period (B). (C) Color scatter plots of pictures
from intestinal epithelial sections of mice after the oil application (upper panel) and Mander’s co-localization coefﬁcient (lower panel) for channel 1 (M1;
ApoA-I) and channel 2 (M2, Rab2). (D) Co-staining of ARFRP1 and Golgin-245 (upper panels), ApoA-I and Golgin-245 (middle panels) and Rab2 and
ApoA-I (lower panels) in Caco-2 cells. (E) Co-localization of Rab2 with ApoA-1 and ARFRP1 in Golgi subcellular fractions. Subcellular fractions were isolated
from differentiated Caco-2 cells with OptiPrepTM as described in Materials and methods. Indicated proteins in the fractions were concentrated and analyzed by
western blotting.
Human Molecular Genetics, 2012, Vol. 21, No. 14 3137associated with membranes of the Golgi. In contrast, in
Arfrp1
vil2/2 cells, Rab2 was mainly detected at large vesicular
structures adjacent to the nuclei. Interestingly, co-staining of
the sections with antibodies against Rab2 and ApoA-I indi-
cated that Rab2 and ApoA-I are predominantly co-localized
(Fig. 6A and B). The co-localization was most pronounced
in intestinal sections of Arfrp1
vil2/2 mice, but also visible in
the controls (see white arrows in higher magniﬁcations;
Fig. 6A and B). We quantiﬁed the level of co-localization of
Rab2 and ApoA-I (Fig. 6C) by detecting the Mander’s
co-localization coefﬁcient for channel 1 (M1; ApoA-I) and
channel 2 (M2, Rab2). This analysis indicates that about
two-thirds of ApoA-I is indeed co-located with Rab2. As
shown in Figure 6C, we observed a signiﬁcant increase in
the co-localization of the two proteins in the Arfrp1
vil2/2 epi-
thelium after the oil application.
In order to further test this hypothesis, we studied the sub-
cellular localization of ARFRP1, Golgin-245, Rab2 and
ApoA-I in Caco-2 cells. As expected, ARFRP1 and
Golgin-245 were detected in the same compartment close to
the nucleus, presumably the trans-Golgi (Fig. 6D, top
panels). Furthermore, ApoA-I was co-localized with
Golgin-245 (Fig. 6D, middle panels), and Rab2 with ApoA-I
(Fig. 6D, bottom panels), supporting our conclusion that
Rab2 may be involved in correct targeting of ApoA-I to chy-
lomicrons in the Golgi apparatus. Similar results were
obtained in subcellular fractions of Caco-2 cells. Western
blot analysis of the subcellular fractions showed a
co-localization of ARFRP1, Rab2 and ApoA-I in the trans-
Golgi compartment, as indicated by the trans-Golgi marker
Syntaxin6 (Fig. 6E). In order to test whether Arfrp1 deletion
affects the localization of COPII which together with Sar1 is
essential for the transport of chylomicrons from the ER to
the Golgi apparatus, we stained intestinal sections with an
anti-COPII antibody. As shown in Supplementary Material,
Figure S9, COPII is mainly located in the perinuclear region
in control and Arfrp1
vil2/2 enterocytes without distinctive dif-
ferences, suggesting the normal subcellular transport of pre-
chylomicrons between ER and Golgi.
Furthermore, we tested this hypothesis by suppressing the
expression of Arl1, Golgin-245 and Rab2 in Caco-2 cells
and by detecting accumulation and release before and after
the oil load. Similar to the effects observed after the suppres-
sion of Arfrp1 (Fig. 2E), the cellular triglyceride content was
signiﬁcantly elevated, whereas the release at the basal site
was markedly reduced after depleting the mRNA of Arl1
(Fig. 7A), Golgin-245 (Fig. 7B) or Rab2 (Fig. 7C).
DISCUSSION
In this work, we discovered the important role of the Golgi for
the ﬁnal lipidation of chylomicrons in the small intestine. We
demonstrate that the trans-Golgi protein ARFRP1 plays an im-
portant role (i) for the lipidation of chylomicrons in the Golgi
and (ii) the assembly of ApoA-I to the chylomicron. The
intestine-speciﬁc Arfrp1 null mutant mice showed reduced
lipid absorption which resulted in the early postnatal growth
retardation. Particularly, both Arfrp1 intestine-speciﬁc knock-
out mice and Arfrp1 depleted Caco-2 cells displayed changes
in the composition of released Apo, indicating that ARFRP1 is
involved in chylomicron maturation.
The assembly of chylomicrons starts in the ER where ApoB
is translated and bound to the lipid core which is transferred by
MTP to this compartment in order to generate the nascent lipo-
protein particles (14–16). ApoA-IV is added to nascent parti-
cles in the ER to provide the surface stability of the particles
(17). Subsequently, pre-chylomicrons bud off from the ER
Figure 7. Impaired triglyceride release from Caco-2 cells after the suppression
of Arl1 (A), Golgin-245 (B) and Rab2 (C) expression. Caco-2 cells were trans-
fected with scrambled or the indicated siRNAs and harvested 8 days after
transfection for western blotting with the different antisera (top panels).
Caco-2 cells were incubated with 4 mM oleic acid for 24 h, and triacylglycerol
levels were measured in the cells (left panels) and the basal media (right
panels).
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chylomicrons receive more lipids by MTP (18). All these steps
appear not to be affected in Arfrp1
vil2/2 mice (see below).
ApoA-I, which is released to a markedly reduced amount
from Arfrp1
vil2/2 enterocytes (Figs 4 and 5), is also generated
in the ER but transported to the Golgi separately from pre-
chylomicron vesicles (Fig. 8) and added to the chylomicrons
before the mature particle is secreted into the lymph (3,18).
Our data suggest that ARFRP1 plays a very speciﬁc role in
the ﬁnal lipidation of chylomicrons within the Golgi. We
suggest that the ﬁrst step of the pre-chylomicron maturation,
the assembly of ApoB48 and lipid load in the ER, is not
affected by the deletion of Arfrp1, because (i) ApoB48 is
released (Fig. 4), (ii) MTP activity is not reduced (Supplemen-
tary Material, Fig. S8) and (iii) the localization of COPII,
known to be required for the generation of PCTVs in the intes-
tinal ER, is not altered in Arfrp1
vil2/2 mice (Supplementary
Material, Fig. S9). However, we cannot prove certainly that
the impact of Arfrp1 deﬁciency on chylomicron biogenesis
is a direct effect of Golgi (TGN) function or an indirect
effect of downstream trafﬁcking perturbations resulting from
an altered Golgi. The fact that not only the depletion of
Arfrp1 but also that of three other proteins that are acting on
the trans-site of the Golgi, ARL1, Golgin-245 and Rab2,
results in impaired release of triglycerides (Fig. 7), supports
our hypothesis that Arfrp1 plays a speciﬁc role for the ﬁnal
lipidation of chylomicrons in the Golgi.
Our data indicate that the lipidation of chylomicrons in the
Golgi and the assembly of ApoA-I to the chylomicron is
impaired in Arfrp1
vil2/2 intestine, because the amounts of
both triacylglycerol and ApoA-I were markedly reduced in
the chylomicron fraction (Fig. 4C). This is supported by the
fact that Arfrp1 depleted Caco-2 cells released signiﬁcantly
less triacylglycerol (Fig. 2C–E) and ApoA-I (Fig. 5A and
B). On the other hand, our data clearly demonstrate that the
assembly of ApoA-I is not required for an appropriate lipida-
tion of chylomicrons, because the suppression of ApoA-I
expression in Caco-2 cells did not reduce the triacylglycerol
release (Fig. 5C). We therefore conclude that the lipidation
of chylomicrons in the Golgi occurs before ApoA-I is attached
to these particles. It is described that MTP delivers the lipid
core to ApoB not only in the ER but also—for further matur-
ation of the particles—in the Golgi (18,19). Since we did not
detect a reduced MTP activity in total lysates of Caco-2 cells
in which Arfrp1 expression was suppressed, we conclude that
ARFRP1 does not modify MTP function.
ARFRP1 is located at the Golgi where it regulates the
recruitmentofARL1toGolgimembranes(7,9,10).Wehavere-
cently shown that ARL1 is dislocated from the trans-Golgi to
the cytosol in the intestinal epithelium of Arfrp1
vil2/2 mice
(8). ARL1 itself binds GRIP domain proteins such as
Golgin-245 and initiates their sorting to the Golgi (20).
Recently, Sinka et al.( 13) discovered an interaction of four
Rabs with GRIP proteins, suggesting a connection between
ARL and Rab protein pathways. Two Rab proteins, Rab2
(Fig. 6) and Rab6, exhibited altered distribution in epithelial
cells of Arfrp1
vil2/2 mice and enhanced mRNA expression
(data not shown). Rab2 is described to be involved in the regu-
lationofthe vesicletransportbetween theERandthecis-Golgi.
The expression of a constitutively active Rab2 mutant resulted
in an impaired anterograde transport from the ER to the Golgi
and an accumulation of vesicles in pre-Golgi membranes
(21,22). We believe that as a consequence of the constant cyto-
solic localization of ARL1 in the Arfrp1
vil2/2 epithelial cells
(8), Golgin-245 cannot be recruited to the trans-Golgi to facili-
tate the further transport of Rab2 vesicles through the Golgi
(Fig. 7). However, up to now, we only can speculate that
Rab2 associates with Golgin-245 or Golgin-97 in the intestinal
epithelium because a direct interaction has not been shown so
far. The ﬁnding that the knockdown of Arl1 as well as that of
Rab2 resulted in a similar reduction in triglyceride release in
Caco-2cells(Fig.7)supportsourhypothesisbutdoesnotdirect-
ly prove the direct connection of these proteins. Additional
studieswillbenecessarytotestwhetherRab2isphysicallyasso-
ciated with one of the golgin proteins.
In other words, the interaction between Rab2 and the
ARL1-regulated scaffolding proteins Golgin-245 and
Golgin-97 might be necessary for Rab2 to be released from
the Golgi for further vesicular trafﬁcking. Interestingly,
Rab2 co-localized with ApoA-I which accumulated in
Figure 8. Model of the role of the ARFRP1-ARL1-Golgin-Rab2 cascade for
chylomicron maturation. (A) ARFRP1 is necessary to recruit ARL1 to the
Golgi, ARL1 binds to the GRIP domain of the scaffolding protein
Golgin-245 which binds Rab2 via the coiled-coil domain. (B) Chylomicron
formation in the ER and the Golgi. In the ER, monoacylglycerol acyltransfer-
ase (MGAT) and diacylglycerol acyltransferase (DGAT) catalyze the synthe-
sis of triacylglycerol (TAG) which is incorporated into ApoB48-containing
pre-chylomicrons. Subsequently, ApoA-IV binds to the pre-chylomicrons
which are then released to the cis-Golgi and further lipidated in the Golgi.
ApoA-I is synthesized in the ER and transported to the Golgi where it is
attached to the chylomicrons. ApoA-I loaded chylomicrons are then trans-
ported through the Golgi, released on the trans-site and ﬁnally secreted into
the lymph. We propose that the ARFRP1-ARL1-Golgin-Rab2 cascade is
needed for an appropriate chylomicron assembly of ApoA-I, its transport
through and lipidation within the Golgi.
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vil2/2 cells and showed a marked reduction in its
release in Arfrp1
vil2/2 mice (Fig. 4) and Arfrp1 knockdown
Caco-2 cells (Fig. 5). Furthermore, the fractionation of
Caco-2 cells indicated that the major amount of Rab2 and
ApoA-I are present in the trans-Golgi compartment
(Fig. 6E). We therefore hypothesize that in enterocytes, the
ARFRP1-ARL1-Golgin-Rab2 cascade is required for the
ﬁnal lipidation of chylomicrons and the transport of ApoA-I
to the chylomicrons in the Golgi to complete the chylomicron
maturation but that ARFRP1 acts independent and down-
stream of COPII and Sar1 (Fig. 8).
Several human diseases are characterized by defects in the
synthesis and the secretion of the ApoB-containing lipopro-
teins. Familial hypobetalipoproteinemia is caused by muta-
tions in the APO-B gene and is characterized by abnormally
low plasma concentrations of ApoB and LDL cholesterol.
Another syndrome with defective chylomicron formation, abe-
talipoproteinemia, is caused by mutations in the gene for MTP.
This defect associates with very low plasma cholesterol and
triacylglycerol levels, the absence of plasma ApoB and a
lipid malabsorption syndrome (23). The third ApoB deﬁciency
syndrome, Anderson’s disease or chylomicron retention
disease, is caused by mutations in the SARA2 gene (protein
Sar1b) (24–26). Sar proteins are members of the ARF
family of GTPases like ARFRP1 and located at the ER (6),
and their defects result in severe fat malabsorption (27). All
chylomicron formation defects known so far are caused by
alterations in the pre-chylomicron assembly. However, our
data indicate that the trafﬁcking and maturation of chylomi-
crons in the Golgi are also crucial steps for the normal lipid
absorption as the defects in these steps affect lipid release
from the mucosa and the whole-body lipid homeostasis.
The absorption of dietary fat is also of increasing concern
because it participates in the rise of adiposity. Interestingly, in-
testinal chylomicron production is up-regulated in humans
under conditions of insulin resistance. This chylomicron over-
production contributes to the highly prevalent dyslipidemia of
insulin resistant patients (28). Therefore, our data signiﬁcantly
contribute toward the development of novel therapeutic strat-
egies for treatments and the prevention of atherosclerosis and
cardiovascular disease.
MATERIALS AND METHODS
Arfrp1
vil2/2 mice
The generation of intestine-speciﬁc Arfrp1 null mutants was
described before (8). In order to rescue the Arfrp1
vil2/2
mice, they were fed with carbohydrate-free high-fat diet
(C1057 Sonderdia ¨t; Altromin Spezialfutter, Lage, Germany)
or a fat-depleted diet consisting of 26.5, 73.2 and 0.2% of cal-
ories from protein, carbohydrates and fat, respectively. All
animal experiments were approved by the ethics committee
of the Ministry of Agriculture, Nutrition, and Forestry (State
of Brandenburg, Germany).
RNA preparation and ﬁrst-strand cDNA synthesis
Total RNA from different tissues of the mice was extracted and
cDNA synthesis was performed as described previously (29).
The quality of cDNA was controlled by PCR with murine
GAPDH primers (forward: 5′-ACC ACA GTC CAT GCC ATC
AC-3′,r e v e r s e :5 ′-TCC CAC CAC CCT GTT GCT GTA-3′).
Quantitative real-time PCR
Quantitative real-time PCR analysis was performed with the
Applied Biosystems 7300 Real-time PCR System as described
previously (29). Expression assays used for the determination
of mRNA levels in jejunum are listed in Supplementary Mater-
ial,TableS1.Datawerenormalizedasdescribed(29),whereasa
b-actin expression assay was used as an endogenous control.
Body composition
For the examination of body fat and lean mass, a nuclear res-
onance spectrometer (Bruker-Mini-Spec-NMR-Analyzer
mq10, Bruker Optics, Houston, USA) was used.
Plasma analysis
Blood glucose levels, plasma triglyceride and free fatty acid
concentrations were determined as described (30).
Glucose tolerance test
Animals at the age of 5 weeks were fasted for 16 h prior to an
oral application of glucose (20% solution, 2 g/kg body weight)
and blood glucose concentrations were measured at 0, 7.5, 15,
30, 60 and 120 min from the tail tip.
Fat tolerance test
Five-week-old mice were fasted for 16 h and received 10 ml/g
olive oil per gavage. Blood samples (30 ml) were collected via
the tail vein prior to (basal, time 0) and 2, 3, 4, 6 and 12 h after
theoraloilapplicationforthedeterminationofplasmatriglyceride.
Detection of intestinal triglyceride secretion after the oil
application and inhibition of lipoprotein lipase
Five-week-old mice were fasted for 5 h and received 10 ml/g
olive oil per gavage. Twenty minutes later, Triton WR-1339
(15% in saline, 0.5 g/kg) was injected intravenously. About
30 ml blood samples were collected via the tail vein prior to
and 30, 60 and 90 min after injection for the determination
of plasma triglyceride concentrations. Mice were sacriﬁced
and blood was collected by cardiac puncture, 100 min after
Triton WR-1339 injection.
Oil-red O staining of intestinal sections
Cryosections of intestine of Arfrp1
ﬂox/ﬂox and Arfrp1
vil2/2
animals were incubated with 0.3% oil-red O for 10 min,
washed with 60% isopropanol and mounted in DAKO Fara-
mount aqueous mounting medium.
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We used the polyclonal antiserum against recombinant
GST-ARFRP1 as described before (4,6). Commercial avail-
able antibodies used for western blotting and immunohisto-
chemistry are listed in Supplementary Material, Table S2.
Immunohistochemistry
Parafﬁn sections of the small intestine of Arfrp1
ﬂox/ﬂox and
Arfrp1
vil2/2 animals at the age of 4 weeks were dewaxed in
toluene and rehydrated. Antigen demasking was performed
by heat treatment (microwave, 2.5 min, 850 W) in 10 mM
Na-citrate, pH 6.0. Unspeciﬁc binding sites were blocked
with the DAKO antibody diluent for 30 min. The indicated
primary antibodies were applied overnight at 48C in a humid
chamber.
Subcellular distribution of SGLT1, Rab2, Rab6, ApoB48,
ApoA-I and ApoA-IV was visualized by ﬂuorescence-
conjugated secondary antibodies. The sections were mounted
in ﬂuorescent mounting medium (Vectashield, Vector Labs,
Burlingame, CA, USA) and analyzed with a Leica TCS SP2
Laser Scan inverted microscope. The intestinal tissues were
sequentially scanned with an argon-krypton laser (488 nm)
to excite the Alexa488 dye and with a helium-neon laser
(543 nm) to excite the Alexa546 dye. The spectral detector
recorded light emission at 510–560 and 580–660 nm, respect-
ively. Images of 1024 × 1024 pixels were processed with
Corel PHOTO-PAINT 10.0 (Coral Corporation).
Caco-2 cells and siRNA mediated suppression of Arfrp1
expression
Caco-2 cells were cultured in DMEM containing high glucose,
L-glutamine, 10% FBS and 1% penicillin–streptomycin.
Transfection was performed as described. (31). Cells were
transfected with 100 pmol/well scrambled or Arfrp1 targeting
siRNA using Lipofectamine 2000 (Invitrogen) in a
12-transwell system. Cells were maintained for 8 days on
the transwell system with a medium change every 2 days.
Caco-2 cells were oil-loaded with DMEM with 10% FBS
and oleic acid:taurocholate complex (ﬁnal concentration
4:0.5 mM) in the apical part for 24 h before harvest, while
DMEM containing 0.1% FBS was supplied in the basal
layer. On the culture day 8, cell layer and the basal medium
were harvested for western blotting.
Detection of triglyceride on Caco-2 cells
Differentiated Caco-2 cells in a 6-transwell system were
treated with 4 mM oleic acid for 24 h. Cells were harvested
in 100 ml/well HB buffer and homogenized by needle-through
with a 25G syringe, while lipids in the basal medium were
extracted in chloroform–methanol (2:1, v/v), dried and resus-
pended in HB buffer. Triglyceride levels were estimated using
Randox TR210 (Randox) according to the manufacturer’s in-
struction.
Subcellular fraction of Caco-2 cells
Caco-2 cells maintained in a 6-transwell system were har-
vested in homogenization buffer [0.25 M sucrose, 1 mM
EDTA, 20 mM HEPES KOH (pH7.4), protease inhibitor] and
homogenized by needle-through with a 25G syringe. After re-
moving the nuclei by centrifuging at 1500g for 10 min at 48C,
the homogenate was separated by Optiprep
TM density gradient
centrifugation according to the manufacturer’s instruction
(Axis-Shield, UK). The gradient was collected in 1 ml of frac-
tions at the end of the centrifugation. Proteins in the fractions
were concentrated using trichloroacetic acid (TCA) to be ana-
lyzed by western blotting.
MTP assay
Caco-2 cells were harvested and sonicated in homogenization
buffer [10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, protease inhibitor]. The MTP assay was performed
by incubating 100 mg of protein with 10 ml of donor solution
and 10 ml of acceptor solution in total volume of 250 ml for
3 h at 378C (Roar Biomedical, NY, USA). The ﬂuorescence
at 465 nm excitation and 538 nm emission wavelength was
measured every 10 min. The results are expressed in arbitrary
units corresponding to the ﬂuorescence intensity transfer per
minute.
Electron microscopy
Small intestine was ﬁxed with 2.5% glutaraldehyde and 2%
paraformaldehyde. Samples were rinsed in 0.1 M phosphate
buffer and post-ﬁxed with 1% osmiumtetroxide, dehydrated
in ascending concentrations of methanol and propylenoxide
and embedded into Epoxy resin. Blocks were trimmed, sec-
tioned and viewed on the FEI EM 208 transmission electron
microscope at ×13 000 magniﬁcation. Negatives were
scanned at 800 dpi.
Western blot analysis
Scraped intestinal mucosa from Arfrp1
vil2/2 and Arfrp1
ﬂox/ﬂox
mice were homogenized and centrifuged for 1 h at 200 000g at
48C. Membrane proteins (20 mg) were separated by SDS–
PAGE and transferred onto nitrocellulose. For immunochem-
ical detection, membranes were incubated with indicated
primary antibodies and subsequently with secondary goat anti-
rabbit IgG (H + L) peroxidase-conjugated antibody or rabbit
anti-mouse IgG Fc-fragment peroxidase-conjugated antibody
(1:20 000; Dianova, Hamburg, Germany).
Apos from Caco-2 cells were determined by western blot-
ting of culture medium (ApoA-I and ApoA-IV, 35 ml;
ApoB, TCA precipitation of 700 ml) and cell lysates (30 mg
supernatant of an RIPA homogenate).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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